Tripelennamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H21N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3C5ORO99TY, chemically known as 1,2-ethanediamine, n, n-dimethyl-n- (phenylmethyl)-n-2-pyridinyl-, monohydrochloride but generally known as tripelennamine, which bears US NIH Compound Identifier 5587. European Medicines Agency schedules Tripelennamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11322MIG. The term TRIPELENNAMINE is an International Non-Proprietary Name. World Health Organization schedules tripelennamine in its Anatomical Therapeutic Chemical (ATC) Classification. TRIPELENNAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tripelennamine under HS 29333999 and SITC 51574. As of Q4 2014, TRIPELENNAMINE remains the US FDA Preferred Term for this commodity. Tripelennamine bears US NLM identifiers UMLS ID C0041090 and NCI Concept Code C61991. SMILES: N(CCN(C)C)(CC1CCCCC1)C1NCCCC1.